The Fallacy of the CE Mark (Revised Content)

Due to a Notice of Concern issued under s14(2) of the Defamation Act 2005 (NSW) by Oncosil Limited (ASX : OSL), this content has been re-posted without any reference to OSL. Thanks to readers who gave me feedback that the content was useful and should be re-posted in a redacted form. Everyone loves the CE (Conformité…

Novogen : Unacceptable Behaviour (Part II)

In this continuation of my prior rant about Novogen CEO Graham Kelly’s questionable interactions with shareholders on HotCopper, I want to specifically review each of the “questions” that appeared on HotCopper and perhaps share some perspectives that will help you to understand why I really despise this kind of informal chit-chat. I note that I have…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…

Cock-a-doodle-doo…

I’m abroad at the moment and I have been getting up very early each day to try and catch up on the morning news back in Australia. Fortunately, a lot of people have also been helping me to stay on top of news flow while I am away and several people forwarded me Tony Boyd’s…

SIRFLOX : OS v PFS

In previous posts I have expressed my opinion that the spectacular pummeling of Sirtex followed by a fairly meteoric rise earlier this week was basically due to the fact that retail investors don’t understand the basics of clinical trials. I do think that Sirtex did a lousy job with communication (this week’s communication exercise was…

What’s not to love about Sirtex?

I’ll start by saying that I have always liked Sirtex, but then I am one of those weird guys that find radiopharmaceuticals intriguing. They’re like something out of a Marvel comic and I have wasted far too much of my career playing around with radiopharma, one of the most brutal areas of life sciences to actually make money. When…